Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Overview: We are seeking dedicated and results-driven Access and Reimbursement Manager (ARMs) to join our team. In this role, you will serve as the primary field-based resource to support practices in ensuring optimal patient access to a large pharmacy benefit specialty product. You will collaborate closely with healthcare providers and internal teams to address access barriers, deliver patient-centric solutions, and educate stakeholders on reimbursement processes.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Number of Employees
501-1,000 employees